Across TCGA pan-cancer cohorts, AKR1C4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AKR1C4 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AKR1C4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated AKR1C4 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where AKR1C4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.267	0.746	.001	41	view →
PDAC	DFS	Tertile	II,III,IV	0.157	0.625	.026	3	view →
CCRCC	DFS	Quartile	IV	0.156	0.961	.038	3	view →
HNSC	DFS	Median	III,IV	1.000	0.841	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: AKR1C4 tumor-vs-normal RNA expression · all AKR1C4 data types